Similarly, CD133 is defined as a cancer stem cell marker, it had been reported in a review done by Brugnoli et al. [46], that it can be considered a poor prognostic factor and indicator of malignant progression in breast cancer patients. This evidence concerns the gene PROM1 and breast cancer.